[SCHEDULE 13G/A] Eledon Pharmaceuticals, Inc. Amended Passive Investment Disclosure

Rhea-AI Filing Summary

BlackRock, Inc. has filed an amended ownership report showing that it beneficially owns 3,625,824 shares of Eledon Pharmaceuticals, Inc. common stock, representing 4.6% of the outstanding class as of the event date. BlackRock reports sole voting power over 3,584,479 shares and sole dispositive power over 3,625,824 shares, with no shared voting or dispositive power.

The filing states that these securities are held by certain BlackRock business units in the ordinary course of business and are not held for the purpose of changing or influencing control of Eledon Pharmaceuticals. The filing also notes that various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of Eledon’s total outstanding common shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Eledon Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

28617K101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 28617K101

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,584,479.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,625,824.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,625,824.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Eledon Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 19800 MACARTHUR BLVD., SUITE 250 IRVINE CA 92612
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 28617K101
Item 4.	Ownership
(a)	Amount beneficially owned: 3625824
(b)	Percent of class: 4.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3584479
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3625824
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Eledon Pharmaceuticals, Inc.. No one person's interest in the common stock of Eledon Pharmaceuticals, Inc. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	01/21/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7

FAQ

How many Eledon Pharmaceuticals (ELDN) shares does BlackRock beneficially own?

BlackRock, Inc. reports beneficial ownership of 3,625,824 shares of Eledon Pharmaceuticals, Inc. common stock, as stated in the ownership section of the filing.

What percentage of Eledon Pharmaceuticals (ELDN) does BlackRock own?

BlackRock reports that its beneficial ownership of Eledon Pharmaceuticals, Inc. common stock represents 4.6% of the outstanding class.

How much voting power does BlackRock have in Eledon Pharmaceuticals (ELDN)?

BlackRock reports sole voting power over 3,584,479 shares of Eledon Pharmaceuticals, Inc. common stock and no shared voting power.

Is BlackRock seeking to control Eledon Pharmaceuticals (ELDN) with this stake?

No. BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Eledon Pharmaceuticals, Inc.

Who ultimately benefits from the Eledon Pharmaceuticals (ELDN) shares held by BlackRock?

The filing states that various persons have the right to receive dividends or sale proceeds from the Eledon Pharmaceuticals, Inc. shares held by BlackRock’s business units, and that no single person’s interest exceeds five percent of the total outstanding common shares.

What type of reporting entity is BlackRock in this Eledon (ELDN) filing?

BlackRock, Inc. is classified as a HC (holding company) reporting person, reflecting that the securities are held by certain of its business units and affiliates.

Who signed the amended Schedule 13G/A for BlackRock regarding Eledon (ELDN)?

The statement was signed by Spencer Fleming, identified as a Managing Director, certifying the accuracy of the information to the best of his knowledge and belief.